SG11202006262TA - Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof - Google Patents

Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof

Info

Publication number
SG11202006262TA
SG11202006262TA SG11202006262TA SG11202006262TA SG11202006262TA SG 11202006262T A SG11202006262T A SG 11202006262TA SG 11202006262T A SG11202006262T A SG 11202006262TA SG 11202006262T A SG11202006262T A SG 11202006262TA SG 11202006262T A SG11202006262T A SG 11202006262TA
Authority
SG
Singapore
Prior art keywords
preparation
application
compound capable
method therefor
tumor inhibitor
Prior art date
Application number
SG11202006262TA
Inventor
Lei Yin
Zhenglin Yao
Heng Li
Original Assignee
Gan & Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan & Lee Pharmaceuticals filed Critical Gan & Lee Pharmaceuticals
Publication of SG11202006262TA publication Critical patent/SG11202006262TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202006262TA 2017-12-29 2018-12-21 Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof SG11202006262TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711484280 2017-12-29
PCT/CN2018/122796 WO2019128877A1 (en) 2017-12-29 2018-12-21 Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof

Publications (1)

Publication Number Publication Date
SG11202006262TA true SG11202006262TA (en) 2020-07-29

Family

ID=67066531

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006262TA SG11202006262TA (en) 2017-12-29 2018-12-21 Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof

Country Status (16)

Country Link
US (1) US11339171B2 (en)
EP (1) EP3733676A4 (en)
JP (1) JP2021508727A (en)
KR (1) KR20200105837A (en)
CN (1) CN112041320B (en)
AU (1) AU2018398881A1 (en)
BR (1) BR112020013069A2 (en)
CA (1) CA3087110A1 (en)
CL (1) CL2020001685A1 (en)
CO (1) CO2020009271A2 (en)
EA (1) EA202091583A1 (en)
IL (1) IL275667A (en)
MX (1) MX2020006816A (en)
PE (1) PE20211908A1 (en)
SG (1) SG11202006262TA (en)
WO (1) WO2019128877A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109464C2 (en) * 2010-11-12 2015-08-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Spiro-oxindoles as mdm2 antagonists
WO2013080141A1 (en) * 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
UY34591A (en) * 2012-01-26 2013-09-02 Novartis Ag IMIDAZOPIRROLIDINONA COMPOUNDS
JP6171003B2 (en) * 2012-05-24 2017-07-26 ノバルティス アーゲー Pyrrolopyrrolidinone compounds
US10138251B2 (en) * 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US9745314B2 (en) * 2014-04-17 2017-08-29 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
CA2947134A1 (en) * 2014-06-12 2015-12-17 Adamed Sp. Z O.O. Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
WO2016001376A1 (en) * 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017060431A1 (en) * 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

Also Published As

Publication number Publication date
CL2020001685A1 (en) 2020-09-25
EP3733676A1 (en) 2020-11-04
WO2019128877A1 (en) 2019-07-04
CA3087110A1 (en) 2019-07-04
US11339171B2 (en) 2022-05-24
IL275667A (en) 2020-08-31
BR112020013069A2 (en) 2020-12-01
MX2020006816A (en) 2020-09-03
EA202091583A1 (en) 2020-10-08
US20210079007A1 (en) 2021-03-18
KR20200105837A (en) 2020-09-09
JP2021508727A (en) 2021-03-11
CO2020009271A2 (en) 2020-08-10
PE20211908A1 (en) 2021-09-28
CN112041320B (en) 2023-05-23
CN112041320A (en) 2020-12-04
EP3733676A4 (en) 2021-09-01
AU2018398881A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
EP3594214A4 (en) Polymorph of compound, preparation method therefor and use thereof
IL272367A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3600318A4 (en) Methods of using ehmt2 inhibitors
EP3589284A4 (en) Uses of pyrimidopyrimidinones as sik inhibitors
EP3429635A4 (en) Anti-crispr compounds and methods of use
EP3504213A4 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
EP3317273A4 (en) Inhibitors of egfr and methods of use thereof
EP3589319A4 (en) Glycan-interacting compounds and methods of use
EP3377070A4 (en) Compounds and methods of their use
GB201514756D0 (en) Compound and method of use
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
EP3373969A4 (en) Glycan-interacting compounds and methods of use
EP3495354A4 (en) Ido1 inhibitor and preparation method and application thereof
HK1232229A1 (en) Novel compound of 4-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof 4-
EP3564253A4 (en) Antidepressant compound and preparation method and application thereof
EP3373910A4 (en) Echinomycin formulation, method of making and method of use thereof
ZA201901717B (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EP3349579A4 (en) Substituted heteroaryl compounds and methods of use
EP3541847A4 (en) Glycan-interacting compounds and methods of use
EP3500257A4 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
EP3305793A4 (en) Derivative of nitrogen-doped phenalene-3-ketone, preparation method therefor and application of derivative used as parp inhibitor
EP3697791A4 (en) Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
EP3710006A4 (en) Substituted heteroaryl compounds and methods of use
EP3347097A4 (en) Substituted heteroaryl compounds and methods of use